NEW YORK, NY — Anavex Life Sciences Corp., a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) disorders, today announced a peer-reviewed publication in Clinical Pharmacology in Drug Development, findings from...
Latest News
New York, NY – Anavex Life Sciences was hit with a stock selloff on Tuesday after it posted topline results from a Phase II/III study for its candidate ANAVEX2-73 in pediatric patients with Rett syndrome. The study’s co-primary endpoint of the Clinical Global Impression-Improvement scale (CGI-I) was not reached, according...
Cambridge, UK – Researchers have created the world’s largest ancient human gene bank by analysing the bones and teeth of almost 5,000 humans who lived across western Europe and Asia up to 34,000 years ago. By sequencing ancient human DNA and comparing it to modern-day samples, the international team of...
COLUMBUS, Ohio — Andelyn Biosciences, Inc., a leading and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has successfully manufactured a novel viral vector gene therapy with its AAV Curator® Platform to treat a baby with the ultra-rare disease Neurodevelopmental Disorder with Regression, Abnormal Movements, Loss of Speech, and Seizures...
COLUMBUS, Ohio — Andelyn Biosciences Inc., a patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), today announced the unveiling of The Andelyn Foundation, a nonprofit organization dedicated to supporting families living with rare and ultra-rare diseases through awareness, fundraising, and compassionate community engagement. More than 10,000 rare diseases have...
COLUMBUS, Ohio — Andelyn Biosciences, Inc., a pioneering and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has partnered with Tern Therapeutics (Tern) to perform late-stage Process Performance Qualification (PPQ) manufacturing of Tern’s TTX-381 program. TTX-381 is an investigational gene therapy targeting vision loss in children with CLN2...
COLUMBUS, Ohio — Andelyn Biosciences, Inc., a pioneering and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), announced that it has been selected by Ultragenyx to perform late-stage Process Performance Qualification (PPQ) manufacturing of the company’s UX111 gene therapy for the potential treatment of Sanfilippo Syndrome (MPS...
WESTLAKE VILLAGE, Calif. — Angitia Biopharmaceuticals, a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for serious musculoskeletal diseases, today announced the dosing of the first patient in the Phase 2 IDUN trial evaluating AGA2115, a bispecific antibody targeting Dickkopf-1 (DKK1) and sclerostin, for the treatment...
WESTLAKE VILLAGE, Calif. — Angitia Biopharmaceuticals, a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for serious musculoskeletal diseases, today announced that data from its ongoing program evaluating AGA2115 for the treatment of osteogenesis imperfecta (OI) will be presented at the American Society for Bone and...
GUILDFORD, SURREY – ANGLE plc, a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) diagnostic solutions for use in research, drug development and clinical oncology, is delighted to announce breakthrough results from DNA molecular analysis of cancer patient blood samples that provide a unique insight into the progression...